Cannabis Law and Access in Malta

A small island with an outsized cannabis law shift

Eighteen drug-related deaths per million population. That was Malta's recorded figure in the years before its government decided the old approach wasn't working. In December 2021, Malta became the first European Union member state to legalise personal cannabis possession and home cultivation for adults. Not just decriminalise it; actually legalise it. For a deeply Catholic, socially conservative country of fewer than 600,000 people, that was not a small step, and Malta's cannabis law has been studied by policy researchers ever since. For general background on the country itself, there is a Wikipedia entry on Malta.

Malta's framework offers an instructive contrast with how Australia approaches cannabis access. The two systems share almost no DNA.

The distinction between decriminalisation and legalisation is the first thing to get straight. Decriminalisation generally means that possession stops attracting criminal penalties, though the substance usually stays prohibited and other sanctions can remain. Legalisation goes further and creates a lawful category of activity with its own rules. Malta's reform created lawful activity for adults, but it did so inside tight limits, which is what the rest of this article unpacks. If you want to compare it with another European model, our piece on cannabis law in the Netherlands shows a very different approach.

The 2021 Act: what it actually permits

The Cannabis Reform Act 2021 (Chapter 618, Laws of Malta), amended via the Authority on the Responsible Use of Cannabis Act, sets the legal architecture. It is worth reading the actual text rather than the press summaries, which tend to swing between "Malta legalised weed" and "Malta went further than the Netherlands." Both framings flatten the detail.

Under the Act, Maltese adults aged 18 and over may:

• possess up to 7 grams of dried cannabis in a public place without criminal liability;
• cultivate up to 4 plants at a private residence, also without criminal liability;
• store up to 50 grams of home-produced cannabis at their residence.

Critically, this is not a free-for-all. Consumption in public, in the presence of minors, or near schools carries civil penalties. The law does not create a commercial retail market in the way that, say, the US state models do. Instead, it establishes a non-profit associative model: licensed Cannabis Clubs.

Two terms in that summary deserve a closer look. "Without criminal liability" does not mean "without any consequence", because civil penalties still sit alongside the permitted conduct. And the quantity limits are tied to location: one figure applies to what a person carries in public, another to what is held at home. Readers who skim a headline number and apply it everywhere are making the most common mistake in discussions of this law.

Cannabis Clubs: the associative model explained

The Cannabis Club structure is probably the most distinctive element of Malta's approach. These are non-profit associations, registered with and overseen by the Authority for the Responsible Use of Cannabis (ARUC), established under the same legislative framework. A club may supply cannabis to its adult members, but cannot operate as a commercial retailer, cannot advertise, and cannot turn a profit in the conventional sense.

Each club is capped at 500 members. Members must be Maltese residents. A single member cannot receive more than 50 grams per month from a club, and no more than 7 grams in a single transaction. The clubs grow their own supply; they cannot source from commercial producers, and are subject to ARUC inspections and record-keeping requirements.

The logic of an associative model is that supply stays inside a closed, small, accountable group rather than flowing through an open market. Membership limits, residency requirements, a ban on advertising and mandatory record-keeping are all tools for keeping the club a club, and not a shopfront by another name. Regulators in other places have wrestled with the same design question. Belgium, for example, has its own history with club-style arrangements, covered in our article on cannabis law in Belgium.

It's an unusual hybrid. Honest assessment: I think the 500-member cap is probably too low to make clubs financially viable in the long run, particularly given the administrative overhead ARUC imposes. But the intent, to separate supply from profit motive, is coherent as a harm-reduction philosophy, even if the implementation is still finding its feet.

Medical cannabis: a separate, older framework

Malta's medical cannabis programme predates the 2021 reform. The country amended its Dangerous Drugs Ordinance and related subsidiary legislation in 2018 to permit prescribing of cannabis-based medicinal products where clinically appropriate. This sits alongside, not within, the adult-use framework.

That separation matters. A medical pathway is built around a clinician's judgement, product quality rules and pharmaceutical oversight, while the adult-use framework is built around personal limits and club membership. The two answer different questions and should not be blended in discussion.

Prescribers must operate within regulatory guidance from Medicines Authority Malta, the equivalent of Australia's TGA. Products must meet pharmaceutical standards including Good Manufacturing Practice, essentially the same GMP principles that govern medicines globally. Imported pharmaceutical-grade products are permitted where locally authorised alternatives don't exist.

The cannabinoids involved are the familiar ones. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the primary active constituents in most authorised products, interacting with the body's endocannabinoid system, specifically at CB1 and CB2 receptors, among other targets. That is a description of pharmacology, not a statement about what any product does for any individual, and evidence quality varies considerably between uses.

CBD specifically: a nuanced position

Low-THC CBD products occupy complicated ground in Malta, as they do across the EU. Under EU Novel Food regulations, CBD extracts for oral consumption technically require authorisation as a novel food; a process that has moved slowly and created inconsistent enforcement across member states.

Malta's position largely follows the European Medicines Agency and European Commission guidance: CBD is not simply a freely tradeable supplement. Higher-concentration products with pharmacological intent fall under medicines law. This means that a full-spectrum extract, one containing CBD alongside other minor cannabinoids, terpenes like myrcene or beta-caryophyllene, and trace THC, does not exist in a regulatory grey zone so much as it exists in a zone where the applicable rules depend on concentration, presentation, and claimed use. The full-spectrum versus isolate distinction matters here more than most people realise.

Why does presentation and claimed use matter so much? Because most medicines regimes classify a product by what it is marketed as being for, as well as by what is in it. The same extract can be treated as a food ingredient, a supplement or a medicine depending on how it is sold. That is a general feature of EU and Australian rules alike, and it explains why two products with similar ingredient lists can face very different obligations.

Malta follows the EU line, which is stricter on CBD than many casual observers assume. Readers who want the primary documents can start with the European Medicines Agency site. For comparison, Italy's treatment of hemp-derived products is covered in our Italy cannabis law article.

What this means for Australians

None of this is Australian law. Worth saying plainly.

In Australia, cannabis containing more than trace THC remains a Schedule 8 controlled drug under the Therapeutic Goods (Poisons Standard, Cannabis) Instrument 2017, as incorporated into the current Poisons Standard. Accessing it legally requires either a valid prescription from an authorised medical practitioner or access via the TGA's Special Access Scheme. The Authorised Prescriber pathway also exists for eligible clinicians who meet the TGA's criteria. The Therapeutic Goods Administration is the authority for those pathways.

Low-dose CBD (below 150 mg/day in certain oral formulations) was down-scheduled to Schedule 3 (pharmacist-only) in 2021, meaning some CBD products are available over the counter from pharmacies without prescription, but these are not the same products available via medical cannabis prescribing pathways, and they remain subject to ARTG listing or registration requirements under the ARTG.

A Maltese Cannabis Club membership is of zero legal relevance once you land at Melbourne Airport or Sydney Kingsford Smith. Bringing cannabis into Australia, regardless of its legal status at origin, is a Commonwealth customs offence.

The broader point is that legality is set by the jurisdiction you are in, not the one you read about. Australia also layers state and territory rules over Commonwealth ones, which is why our explainer on state versus federal drug regulation in Australia is a useful companion read. Ireland and Cyprus, both covered on this site, show how other EU members handle medical access without any adult-use framework: see cannabis law in Ireland and cannabis law in Cyprus.

The ARUC and ongoing regulatory development

Malta's ARUC is a relatively new body and still building its operational infrastructure. As of the most recent public reporting, the number of registered Cannabis Clubs remains small, far fewer than the legislation potentially permits. Implementation has been slower than the 2021 headlines suggested it would be.

This pattern is familiar. Regulatory frameworks that look clean on paper almost always encounter friction when they meet real-world supply chains, banking relationships (cannabis remains federally complex across many jurisdictions for financial services), and enforcement calibration. The same gap between legislative intent and operational reality appeared in early stages of Canada's federal framework and in multiple US state roll-outs.

A sound way to read any reform is to separate three layers: what the statute says, what the regulator has built to administer it, and what actually happens on the ground. Headlines tend to report the first layer only. Licensing backlogs, inspection capacity and the practical difficulty of running a compliant non-profit all sit in the second and third layers, and they determine whether a law changes anything at all.

Malta's experiment is still genuinely young. Watching how ARUC matures its inspection regime and how the club model scales, or doesn't, will be instructive for policy researchers elsewhere, including here.

Sources

• Cannabis Reform Act 2021 (Chapter 618), Laws of Malta
• Malta Drug Report 2023; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Medicinal Cannabis Guidance Documents, Therapeutic Goods Administration (TGA)
• Cannabidiol Article 5(3) Referral Assessment Report, European Medicines Agency (EMA)

Marcus Hale, Regulatory researcher; TGA & access law